Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). Issue 1 (April 2015)

• Record Type: Journal Article
• Authors: Kotsakis, A.; Kentepozidis, N.; Emmanouilidis, Ch.; Polyzos, A.; Agelidou, A.; Vaslamatzis, M.; Chandrinos, V.; Agelaki, S.; Vamvakas, L.; Kalbakis, K.; Katsaounis, P.; Stoltidis, D.; Nintos, G.; Hatzidaki, D.; Vetsika, E.K.; Mavroudis, D.; Georgoulias, V.
• Is Part Of: Lung cancer. Volume 88:Issue 1(2015:Apr.)
• Page Start: 57
• Page End: 62
• Publication Date: 2015-04
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.01.012
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Platinum-based chemotherapy is considered the cornerstone of treatment for NSCLC.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Bevacizumab with sequential chemotherapy is feasible with manageable toxicity.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">This regimen in some cases is very active and leads to durable responses.</p> </list-item> </list> </p> </sec> </abstract>